Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 576

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve‐month, multicenter, randomized, double‐blind, placebo‐controlled, phase II clinical trial

Cohen, Stanley B., Dore, Robin K., Lane, Nancy E., Ory, Peter A., Peterfy, Charles G., Sharp, John T., van der Heijde, Désirée, Zhou, Lifen, Tsuji, Wayne, Newmark, Richard, Denosumab Rheumatoid Arthritis Study Group·2008·Arthritis & Rheumatism

Abstract

Objective: RANKL is essential for osteoclast development, activation, and survival. Denosumab is a fully human monoclonal IgG2 antibody that binds RANKL, inhibiting its activity. The aim of this multicenter, randomized, double‐blind, placebo‐controlled, phase II study was to evaluate the effects of denosumab on structural damage in patients with rheumatoid arthritis (RA) receiving methotrexate treatment. Methods: RA patients received subcutaneous placebo (n = 75), denosumab 60 mg (n = 71), or denosumab 180 mg (n = 72) injections every 6 months for 12 months. The primary end point was the change from baseline in the magnetic resonance imaging (MRI) erosion score at 6 months. Results: At 6 months, the increase in the MRI erosion score from baseline was lower in the 60‐mg denosumab group (mean change 0.13; P = 0.118) and significantly lower in the 180‐mg denosumab group (mean change 0.06; P = 0.007) than in the placebo group (mean change 1.75). A significant difference in the modified Sharp erosion score was observed as early as 6 months in the 180‐mg denosumab group (P = 0.019) as compared with placebo, and at 12 months, both the 60‐mg (P = 0.012) and the 180‐mg (P = 0.007) denosumab groups were significantly different from the placebo group. Denosumab caused sustained suppression of markers of bone turnover. There was no evidence of an effect of denosumab on joint space narrowing or on measures of RA disease activity. Rates of adverse events were comparable between the denosumab and placebo groups. Conclusion: Addition of twice‐yearly injections of denosumab to ongoing methotrexate treatment inhibited structural damage in patients with RA for up to 12 months, with no increase in the rates of adverse events as compared with placebo.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.23417

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Cited by

See all 576

Metadata

Authors
Cohen, S. B., Dore, R. K., Lane, N. E., Ory, P. A., Peterfy, C. G., Sharp, J. T., van der Heijde, D., Zhou, L., Tsuji, W., Newmark, R., & Denosumab Rheumatoid Arthritis Study Group
Venue
Arthritis & Rheumatism
Publisher
Wiley
Published
2008-04-25
Volume
58
Issue
5
Pages
1299-1309
ISSN
  • 0004-3591 (ISSN-L)
  • 1529-0131
OpenAlex
W2058858133
Cited by
576
References
33
FWCI
39.36
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve‐month, multicenter, randomized, double‐blind, placebo‐controlled, phase II clinical trial. https://app.cochat.ai/papers/10.1002/art.23417
The paper
Cohen, S. B., Dore, R. K., Lane, N. E., Ory, P. A., Peterfy, C. G., Sharp, J. T., van der Heijde, D., Zhou, L., Tsuji, W., Newmark, R., & Denosumab Rheumatoid Arthritis Study Group. (2008). Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve‐month, multicenter, randomized, double‐blind, placebo‐controlled, phase II clinical trial. Arthritis & Rheumatism. https://doi.org/10.1002/art.23417

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.